Dalphene Labs · The business of medical aestheticsFor owners, injectors & clinic teamsJoin the brief

Daily edition

Dalphene Labs

Medical aesthetics

Today in brief

01
Dupilumab triggers delayed dermal filler reactions
Patients on this eczema biologic are presenting with swelling at old hyaluronic acid injection sites, requiring careful history-taking before treatment.
02
Under-eye filler demand rises with GLP-1 use
The FDA approval of RHA Redensity Eye arrives as rapid weight loss drives more patients to seek structural volume restoration.
03
State boards tighten rules on compound peptides
South Carolina is blocking clinics from sourcing raw, research-grade active ingredients to mix custom wellness and anti-aging therapies.

60 briefs

Lead · Industry

Revelyx Bio launches to commercialize ready-to-use liquid botulinum toxin YY003

Dalphene Labs · Industry · Published Sep 3, 2026

Revelyx Bio Launches to Develop Ready-to-Use Recombinant Botulinum Toxin

Revelyx Bio has launched with the exclusive global rights to develop and commercialize YY003, an investigational recombinant botulinum toxin type A that aims to eliminate manual reconstitution in your practice. The product is a ready-to-use liquid formulation delivered in a prefilled syringe, produced via an E. coli expression system. For injectors, this format directly targets common clinic pain points around mixing variables, preparation time, and dosing consistency.

Read the full brief →